Status:
TERMINATED
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Lead Sponsor:
Cartesian Therapeutics
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Acute Respiratory Distress Syndrome
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
Eligibility Criteria
Inclusion
- Patients must be 18 years of age or older at the time of enrollment
- Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS
Exclusion
- Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA.
- Patient is in moribund state with expected survival \<24 hours.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2023
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04524962
Start Date
February 23 2021
End Date
September 9 2023
Last Update
October 29 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
2
University of Maryland Medical Center Medical Center
Baltimore, Maryland, United States, 21201